{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:06:15Z","timestamp":1779242775616,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03804-y","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:37:12Z","timestamp":1775893032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["No major effect of age (<\u200940 vs.\u2009\u2265\u200940 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corine","family":"Gaillez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta","family":"Kiltz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitali","family":"Pisal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurgen","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"12","key":"3804_CR1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","volume":"80","author":"V Navarro-Compan","year":"2021","unstructured":"Navarro-Comp\u00e1n V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis Dec. 2021;80(12):1511\u201321. . https:\/\/doi.org\/10.1136\/annrheumdis-2021-221035","journal-title":"Ann Rheum Dis Dec"},{"issue":"4","key":"3804_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MAJ.0b013e31820f8c99","volume":"341","author":"JD Reveille","year":"2011","unstructured":"Reveille JD. Epidemiology of spondyloarthritis in North America. Am J Med Sci Apr. 2011;341(4):284\u20136. https:\/\/doi.org\/10.1097\/MAJ.0b013e31820f8c99.","journal-title":"Am J Med Sci Apr"},{"key":"3804_CR3","doi-asserted-by":"publisher","unstructured":"Boel A, L\u00f3pez-Medina C, van der Heijde D, van Gaalen FA. Age at onset in axial spondyloarthritis around the world: data from the Assessment in SpondyloArthritis international Society Peripheral Involvement in Spondyloarthritis study. Rheumatology (Oxford). Apr. 2022;61(4):1468\u201375. https:\/\/doi.org\/10.1093\/rheumatology\/keab544.","DOI":"10.1093\/rheumatology\/keab544"},{"key":"3804_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215707","author":"A Boel","year":"2019","unstructured":"Boel A, Molto A, van der Heijde D, et al. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Ann Rheum Dis. 2019;78(11):1545\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215707.","journal-title":"Ann Rheum Dis Jul"},{"issue":"5","key":"3804_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/ard-2023-225185","volume":"11","author":"D van der Heijde","year":"2024","unstructured":"van der Heijde D, Molto A, Ramiro S, et al. Goodbye to the term \u2018ankylosing spondylitis\u2019, hello \u2018axial spondyloarthritis\u2019: time to embrace the ASAS-defined nomenclature. Ann Rheum Dis Apr. 2024;(5):547\u20139. https:\/\/doi.org\/10.1136\/ard-2023-22518.","journal-title":"Ann Rheum Dis Apr"},{"issue":"1","key":"3804_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis Jan. 2011;70(1):25\u201331. https:\/\/doi.org\/10.1136\/ard.2010.133645.","journal-title":"Ann Rheum Dis"},{"key":"3804_CR7","doi-asserted-by":"publisher","unstructured":"Schwartzman S, Ruderman EM. Jan. A road map of the axial sp ondyloarthritis continuum. Mayo Clin Proc. 2022;97(1):134\u2013145. https:\/\/doi.org\/10.1016\/j.mayocp.2021.08.007.","DOI":"10.1016\/j.mayocp.2021.08.007"},{"issue":"1","key":"3804_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40744-020-00194-8","volume":"7","author":"E Yi","year":"2020","unstructured":"Yi E, Ahuja A, Rajput T, George AT, Park Y. Clinical, economic, and humanistic burden associated with delayed diagnosis of axial spondyloarthritis: A systematic review. Rheumatol Ther Mar. 2020;7(1):65\u201387. https:\/\/doi.org\/10.1007\/s40744-020-00194-8.","journal-title":"Rheumatol Ther Mar"},{"issue":"8","key":"3804_CR9","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s10067-014-2768-y","volume":"34","author":"MR Seo","year":"2015","unstructured":"Seo MR, Baek HL, Yoon HH, et al. Delayed diagnosis is linked to worse outcomes and unfavourable treatment responses in patients with axial spondyloarthritis. Clin Rheumatol Aug. 2015;34(8):1397\u2013405. https:\/\/doi.org\/10.1007\/s10067-014-2768-y.","journal-title":"Clin Rheumatol Aug"},{"issue":"1","key":"3804_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13075-020-02301-0","volume":"10","author":"I Redeker","year":"2020","unstructured":"Redeker I, Callhoff J, Hoffmann F, et al. The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. Arthritis Res Ther Sep. 2020;10(1):210. https:\/\/doi.org\/10.1186\/s13075-020-02301-0.","journal-title":"Arthritis Res Ther Sep"},{"key":"3804_CR11","doi-asserted-by":"publisher","unstructured":"Zhao SS, Jones GT, Macfarlane GJ, Hughes DM, Moots RJ, Goodson NJ. Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS. Rheumatology (Oxford). 2021;60(9):4158\u201365. https:\/\/doi.org\/10.1093\/rheumatology\/keaa900.","DOI":"10.1093\/rheumatology\/keaa900"},{"issue":"8","key":"3804_CR12","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/acr.23468","volume":"70","author":"E Nikiphorou","year":"2018","unstructured":"Nikiphorou E, Ramiro S, van der Heijde D, et al. Association of comorbidities in spondyloarthritis with poor function, work disability, and quality of life: results from the assessment of SpondyloArthritis international Society Comorbidities in Spondyloarthritis Study. Arthritis Care Res (Hoboken) Aug. 2018;70(8):1257\u201362. https:\/\/doi.org\/10.1002\/acr.23468.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"3804_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis Jan. 2023;82(1):19\u201334. https:\/\/doi.org\/10.1136\/ard-2022-223296.","journal-title":"Ann Rheum Dis Jan"},{"issue":"10","key":"3804_CR14","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken) Oct. 2019;71(10):1285\u201399. https:\/\/doi.org\/10.1002\/acr.24025.","journal-title":"Arthritis Care Res (Hoboken) Oct"},{"issue":"Suppl 2","key":"3804_CR15","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis Jun. 2009;68(suppl 2):ii1\u201344. https:\/\/doi.org\/10.1136\/ard.2008.104018.","journal-title":"Ann Rheum Dis Jun"},{"issue":"6","key":"3804_CR16","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.semarthrit.2021.07.021","volume":"51","author":"V Navarro-Compan","year":"2021","unstructured":"Navarro-Comp\u00e1n V, Boel A, Boonen A, et al. The ASAS-OMERACT core domain set for axial spondyloarthritis. Semin Arthritis Rheum Dec. 2021;51(6):1342\u20139. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.07.021.","journal-title":"Semin Arthritis Rheum Dec"},{"issue":"6","key":"3804_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1136\/annrheumdis-2022-222747","volume":"82","author":"V Navarro-Comp\u00e1n","year":"2023","unstructured":"Navarro-Comp\u00e1n V, Boel A, Boonen A, et al. Instrument selection for the ASAS core outcome set for axial spondyloarthritis. Ann Rheum Dis Jun. 2023;82(6):763\u201372. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222747.","journal-title":"Ann Rheum Dis Jun"},{"issue":"5","key":"3804_CR18","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/annrheumdis-2015-207786","volume":"75","author":"V Navarro-Compan","year":"2016","unstructured":"Navarro-Comp\u00e1n V, Ramiro S, Landewe R, et al. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. Ann Rheum Dis May. 2016;75(5):874\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207786.","journal-title":"Ann Rheum Dis May"},{"key":"3804_CR19","unstructured":"Cosentyx [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 2023. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/cosentyx.pdf"},{"key":"3804_CR20","doi-asserted-by":"publisher","unstructured":"Xie Y, Liu Y, Wu Q. Effect of gender and age on bDMARD efficacy for axial spondyloarthritis patients: a meta-analysis of randomized controlled trials. Rheumatology (Oxford) Nov. 2024;63(11):2914\u201322. https:\/\/doi.org\/10.1093\/rheumatology\/keae088.","DOI":"10.1093\/rheumatology\/keae088"},{"issue":"12","key":"3804_CR21","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1002\/art.39805","volume":"68","author":"AA Deodhar","year":"2016","unstructured":"Deodhar AA, Dougados M, Baeten DL, et al. Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: A phase III randomized trial (MEASURE 1). Arthritis Rheumatol Dec. 2016;68(12):2901\u201310. https:\/\/doi.org\/10.1002\/art.39805.","journal-title":"Arthritis Rheumatol Dec"},{"issue":"26","key":"3804_CR22","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"24","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med Dec. 2015;(26):2534\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1505066.","journal-title":"N Engl J Med Dec"},{"issue":"1","key":"3804_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","volume":"22","author":"K Pavelka","year":"2017","unstructured":"Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther Dec. 2017;22(1):285. https:\/\/doi.org\/10.1186\/s13075-017-1490-y.","journal-title":"Arthritis Res Ther Dec"},{"issue":"1","key":"3804_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","volume":"73","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Blanco R, Dokoupilova E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: Primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol Jan. 2021;73(1):110\u201320. https:\/\/doi.org\/10.1002\/art.41477.","journal-title":"Arthritis Rheumatol Jan"},{"issue":"2","key":"3804_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","volume":"5","author":"AJ Kivitz","year":"2018","unstructured":"Kivitz AJ, Wagner U, Dokoupilova E, et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from mEASURE 4 study. Rheumatol Ther Dec. 2018;5(2):447\u201362. https:\/\/doi.org\/10.1007\/s40744-018-0123-5.","journal-title":"Rheumatol Ther Dec"},{"issue":"21","key":"3804_CR26","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1097\/CM9.0000000000001099","volume":"5","author":"F Huang","year":"2020","unstructured":"Huang F, Sun F, Wan WG, et al. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, phase III China-centric study, MEASURE 5. Chin Med J (Engl) Nov. 2020;133 (21):2521\u201331. https:\/\/doi.org\/10.1097\/CM9.0000000000001099.","journal-title":"Chin Med J (Engl) Nov"},{"issue":"4","key":"3804_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum Apr. 1984;27(4):361\u20138. https:\/\/doi.org\/10.1002\/art.1780270401.","journal-title":"Arthritis Rheum Apr"},{"issue":"6","key":"3804_CR28","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/ard.2009.108217","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Landew\u00e9 R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis Jun. 2009;68(6):770\u20136. https:\/\/doi.org\/10.1136\/ard.2009.108217.","journal-title":"Ann Rheum Dis Jun"},{"issue":"6","key":"3804_CR29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis Jun. 2009;68(6):777\u201383. https:\/\/doi.org\/10.1136\/ard.2009.108233.","journal-title":"Ann Rheum Dis Jun"},{"issue":"3","key":"3804_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.46497\/ArchRheumatol.2023.9793","volume":"38","author":"HF \u00c7ay","year":"2023","unstructured":"\u00c7ay HF, Alkan Meliko\u011flu M, Yurdakul FG, et al. Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar. Arch Rheumatol Sep. 2023;38(3):333\u201346. https:\/\/doi.org\/10.46497\/ArchRheumatol.2023.9793.","journal-title":"Arch Rheumatol Sep"},{"issue":"5","key":"3804_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/acr2.11543","volume":"5","author":"M Magrey","year":"2023","unstructured":"Magrey M, Walsh JA, Flierl S, et al. The International Map of Axial Spondyloarthritis survey: A US patient perspective on diagnosis and burden of disease. ACR Open Rheumatol May. 2023;5(5):264\u201376. https:\/\/doi.org\/10.1002\/acr2.11543","journal-title":"ACR Open Rheumatol May"},{"key":"3804_CR32","unstructured":"Deodhar A, Mease P, Machado P, Meng X, Strand V, Magrey M. Impact of age and disease duration on the response to IL-17A inhibitor (secukinumab) treatment in ankylosing spondylitis: pooled results from the phase 3 measure studies [abstract]. Arthritis Rheumatol Oct. 2019;71(suppl 10). Accessed Nov 10, 2023. https:\/\/acrabstracts.org\/abstract\/impact-of-age-and-disease-duration-on-the-response-to-il-17a-inhibitor-secukinumab-treatment-in-ankylosing-spondylitis-pooled-results-from-the-phase-3-measure-studie."},{"key":"3804_CR33","unstructured":"Deodhar A, Mease P, Machado P, et al. The impact of age and time since diagnosis on response to treatment with secukinumab in pooled week 52 data from 4 phase 3 studies in patients with ankylosing spondylitis [abstract]. Arthritis Rheumatol Oct. 2020;(suppl 10). Accessed Dec 19, 2024. https:\/\/acrabstracts.org\/abstract\/the-impact-of-age-and-time-since-diagnosis-on-response-to-treatment-with-secukinumab-in-pooled-week-52-data-from-4-phase-3-studies-in-patients-with-ankylosing-spondylitis\/."},{"issue":"10","key":"3804_CR34","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/art.39257","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheum Oct. 2015;67(10):2702\u201312. https:\/\/doi.org\/10.1002\/art.39257.","journal-title":"Arthritis Rheum"},{"issue":"10349","key":"3804_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"30","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Jul. 2022;30(10349):369\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(22)01212-0.","journal-title":"Lancet Jul"},{"key":"3804_CR36","doi-asserted-by":"publisher","unstructured":"Jurik AG. Diagnostics of sacroiliac joint differentials to axial spondyloarthritis changes by magnetic resonance imaging. J Clin Med Jan. 2023;12(3):1039. https:\/\/doi.org\/10.3390\/jcm12031039.","DOI":"10.3390\/jcm12031039"},{"issue":"1","key":"3804_CR37","doi-asserted-by":"publisher","first-page":"10342","DOI":"10.1038\/s41598-024-61001-w","volume":"6","author":"J Londono","year":"2024","unstructured":"Londono J, Pacheco-Tena C, Santos AM, et al. Differences between radiographic and non-radiographic axial spondyloarthritis patients in a Mexican cohort. Sci Rep May. 2024;14(1):10342. https:\/\/doi.org\/10.1038\/s41598-024-61001-w.","journal-title":"Sci Rep May"},{"issue":"1","key":"3804_CR38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13075-017-1493-8","volume":"22","author":"N Ghosh","year":"2017","unstructured":"Ghosh N, Ruderman EM. Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance. Arthritis Res Ther Dec. 2017;19(1):286. . https:\/\/doi.org\/10.1186\/s13075-017-1493-8","journal-title":"Arthritis Res Ther Dec"},{"issue":"3","key":"3804_CR39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10067-018-4397-3","volume":"38","author":"A Danve","year":"2019","unstructured":"Danve A, Deodhar A. Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities. Clin Rheumatol Mar. 2019;38(3):625\u201334. https:\/\/doi.org\/10.1007\/s10067-018-4397-3.","journal-title":"Clin Rheumatol Mar"},{"key":"3804_CR40","doi-asserted-by":"publisher","first-page":"1759720X2211003","DOI":"10.1177\/1759720X221100301","volume":"14","author":"TH Lee","year":"2022","unstructured":"Lee TH, Koo BS, Nam B, et al. Age-stratified trends in the progression of spinal radiographic damage in patients with ankylosing spondylitis: a longitudinal study. Ther Adv Musculoskelet Dis May. 2022;14:1759720X221100301. https:\/\/doi.org\/10.1177\/1759720X221100301.","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03804-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03804-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03804-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:35:23Z","timestamp":1779240923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03804-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3804"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03804-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies included in this pooled analysis were approved by central institutional review boards and the ethics review boards at each participating center. Each study was conducted in accordance with the principles of the Declaration of Helsinki, and written informed consent was obtained from all participants before study-related procedures were performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"S.R. has received research grants from AbbVie, Galapagos\/Alfasigma, Novartis, Pfizer, and UCB Pharma and consulting fees from AbbVie, Eli Lilly, Galapagos\/Alfasigma, Janssen, Novartis, MSD, Pfizer, UCB Pharma, and Sanofi. C.G. is an employee of Novartis Pharma AG. U.K. has received grant and research support and consultancy fees from AbbVie, Amgen, Biocad, Biogen, Bristol Myers Squibb, Chugai, Eli Lilly, Fresenius, Gilead, Gr\u00fcnenthal, GSK, Hexal, Janssen, MSD, Novartis, Onkowissen.de, Pfizer, Roche, UCB Pharma, and Viatris. L.S.G. has received consulting fees from Acelyrin, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB Pharma and research support from UCB Pharma. C.P. is an employee of Novartis Healthcare Private Limited. J.B. declares no competing interests. A.O. has received consulting fees from Amgen, AbbVie, Bristol Myers Squibb, Celgene, CorEvitas, Eli Lilly, Gilead, GSK, Happify Health, Janssen, Novartis, Pfizer, and UCB Pharma and has received grant support from the National Institutes of Health\/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation, National Psoriasis Foundation, Amgen, Pfizer, and Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}